Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sunshine Biopharma Inc’s filings rarely read like a conventional pharma report. One section covers steady cash flows from Nora Pharma’s generic prescription roster, the next dives into pre-clinical mRNA-LNP oncology data. Investors looking for Sunshine Biopharma insider trading Form 4 transactions or the latest Sunshine Biopharma quarterly earnings report 10-Q filing need more than raw documents—they need context.
Stock Titan’s AI extracts that context in seconds. Whether it is a sudden Form 4 alert—Sunshine Biopharma Form 4 insider transactions real-time—or a deep dive titled Sunshine Biopharma SEC filings explained simply, our engine highlights pipeline spending, trial updates, and gross-margin shifts side by side. You will also find concise Sunshine Biopharma earnings report filing analysis, perfect for understanding revenue from generics versus R&D burn. For anyone understanding Sunshine Biopharma SEC documents with AI, we connect disclosures directly to the company’s dual strategy.
- Instant alerts for Sunshine Biopharma executive stock transactions Form 4
- Redlined comparisons that make a Sunshine Biopharma annual report 10-K simplified
- Proxy tools spotlighting Sunshine Biopharma proxy statement executive compensation
- Event timelines turning a dense Sunshine Biopharma 8-K material events explained into a two-minute brief
Analysts track insider buys before trial milestones, portfolio managers benchmark quarter-over-quarter generic revenue, and scientists watch PLpro spending trends. Whichever lens you use, Stock Titan delivers every Sunshine Biopharma disclosure in real time, translated into clear insight and ready for action.
Sunshine Biopharma (SBFM) filed its Q3 2025 10‑Q, highlighting year‑over‑year revenue growth and a smaller quarterly loss. Revenue for the quarter reached $9,417,179, up 11.6% from a year ago, with gross profit of $3,073,540. Operating loss was $1,086,613, and net loss narrowed to $883,820, or $0.19 per share.
For the nine months ended September 30, 2025, revenue was $27,728,750 (up 9.7%). Net loss for the period was $3,834,425, reflecting higher G&A and a $1,616,459 impairment of intangible assets tied to product licenses that could not be commercialized. Cash and equivalents were $9,306,438 as of September 30, 2025.
The company completed an April 2025 registered direct offering, receiving $1,828,596 in net proceeds, and reported additional cash from warrant exercises during the year. Shares outstanding were 4,555,945 as of September 30, 2025, and 4,905,945 as of November 13, 2025. Management aims to reduce cost of goods sold toward 60% to move toward breakeven while continuing to expand Nora Pharma’s Canadian generic portfolio.
Sunshine Biopharma (SBFM) will hold its 2025 virtual annual meeting on December 11, 2025 to vote on three items: elect five directors, ratify M&K CPAS, PLLC as auditor, and amend the 2023 Equity Incentive Plan to increase shares authorized for issuance from 1,661 to 683,000.
The record date is October 17, 2025, with 4,905,945 common shares and 130,000 Series B Preferred outstanding. Each Series B Preferred share carries 1,000 votes, and all Series B shares are held by the CEO, concentrating voting power. The Board recommends voting FOR all proposals.
Auditor history was addressed: following the SEC’s settled order permanently barring BF Borgers from practicing before the SEC, the company dismissed Borgers in 2024, engaged Bush & Associates, and on September 24, 2025 appointed M&K CPAS, PLLC. Executive agreements disclose severance terms, including
FAQ
What is the current stock price of Sunshine Biopharma (SBFM)?
What is the market cap of Sunshine Biopharma (SBFM)?
